

Aerosolized Hydrogen Peroxide Decontamination of N95 Respirators, with Fit-Testing and Viral Inactivation, Demonstrates Feasibility for Re-Use During the COVID-19 Pandemic

T. Hans Derr^{1*}, Melissa A. James^{2^}, Chad V. Kuny^{4,8^}, Devanshi Patel^{6,8}, Prem P. Kandel⁵, Cassandra Field^{6,8}, Matthew D. Beckman⁷, Kevin L. Hockett^{5,8}, Mark A. Bates³, Troy C. Sutton^{6,8}, Moriah Szpara^{4,8*}

^co-first-authors

¹ Environmental Health and Safety; ² Animal Resource Program, ³ Occupational Medicine Program, and ⁴ Departments of Biology, Biochemistry and Molecular Biology, ⁵ Plant Pathology and Environmental Microbiology, ⁶ Veterinary and Biomedical Sciences, ⁷ Statistics, ⁸ Center for Infectious Disease Dynamics, and the Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, Pennsylvania 16802, USA

*Co-Corresponding Authors

Moriah L. Szpara, PhD
Depts. of Biology, and Biochemistry & Molecular Biology
The Huck Institutes of the Life Sciences
Pennsylvania State University
W-208 Millennium Science Complex (MSC)
University Park, PA 16802 USA
Phone: 814-867-0008
Email: moriah@psu.edu

T. Hans Derr, CIH
Manager, Health & Environmental Programs
Environmental Health & Safety
Pennsylvania State University
6B Eisenhower Deck
University Park, PA 16802
Phone: 814-863-3834
Email: thd12@psu.edu

Author emails:

Mark A. Bates: mx20@psu.edu
Matthew D. Beckman: mdb268@psu.edu
T. Hans Derr: thd12@psu.edu
Cassandra Field: cif5202@psu.edu
Kevin L. Hockett: klh450@psu.edu
Melissa A. James: maj22@psu.edu

Prem Kandel: kandelprem@gmail.com
Chad V. Kuny: cvk108@psu.edu
Devanshi Patel: drp5323@psu.edu
Troy C. Sutton: tcs38@psu.edu
Moriah L. Szpara: moriah@psu.edu

1 **Abstract**

2 In response to the demand for N95 respirators by healthcare workers during the COVID-19
3 pandemic, we evaluated decontamination of N95 respirators using an aerosolized hydrogen
4 peroxide (aHP) system. This system is designed to dispense a consistent atomized spray of
5 aerosolized, 7% hydrogen peroxide (H₂O₂) solution over a treatment cycle. Multiple N95
6 respirator models were subjected to ten or more cycles of respirator decontamination, with a
7 select number periodically assessed for qualitative and quantitative fit testing. In parallel, we
8 assessed the ability of aHP treatment to inactivate multiple viruses absorbed onto respirators,
9 including phi6 bacteriophage, HSV-1, CVB3, and SARS-CoV-2. For pathogens transmitted via
10 respiratory droplets and aerosols, it is critical to address respirator safety for reuse. This study
11 provided experimental validation of an aHP treatment process that decontaminates the respirators
12 while maintaining N95 function. External NIOSH certification verified respirator structural
13 integrity and filtration efficiency after ten rounds of aHP treatment. Virus inactivation by aHP
14 was comparable to the decontamination of commercial spore-based biological indicators. These
15 data demonstrate that the aHP process is effective, with successful fit-testing of respirators after
16 multiple aHP cycles, effective decontamination of multiple virus species including SARS-CoV-
17 2, successful decontamination of bacterial spores, and filtration efficiency maintained at or
18 greater than 95%. While this study did not include extended or clinical use of N95 respirators
19 between aHP cycles, these data provide proof of concept for aHP decontamination of N95
20 respirators before reuse in a crisis-capacity scenario.

21

22 **Importance**

23 The COVID-19 pandemic led to unprecedented pressure on healthcare and research facilities to
24 provide personal protective equipment. The respiratory nature of the SARS-CoV2 pathogen
25 makes respirator facepieces a critical protection measure to limit inhalation of this virus. While
26 respirator facepieces were designed for single-use and disposal, the pandemic increased overall
27 demand for N95 respirators, and corresponding manufacturing and supply chain limitations
28 necessitated the safe reuse of respirators when necessary. In this study, we repurposed an
29 aerosolized hydrogen peroxide (aHP) system that is regularly utilized to decontaminate materials

30 in a biosafety level 3 (BSL3) facility, to develop methods for decontamination of N95
31 respirators. Results from virus inactivation, biological indicators, respirator fit testing, and
32 filtration efficiency testing all indicated that the process was effective at rendering N95
33 respirators safe for reuse. This proof-of-concept study establishes baseline data for future testing
34 of aHP in crisis capacity respirator-reuse scenarios.

35

36 **Keywords:**

37 N95 respirators, filtering facepiece (FFP) respirators (FFR), decontamination, aerosolized
38 hydrogen peroxide, COVID-19, SARS-CoV2, virologic testing, virus, fit-testing, disinfection,
39 sterilization, CURIS®

40

41 **Abbreviations:**

42 aHP, aerosolized hydrogen peroxide (H₂O₂); BSL, biosafety level; COVID-19, coronavirus
43 disease 2019; CVB3, coxsackievirus B3; H₂O₂, hydrogen peroxide; HPM, hydrogen peroxide
44 vapor monitor; HSV-1, herpes simplex virus 1; phi6, *Pseudomonas* phi6 bacteriophage; OSHA,
45 Occupational Safety and Health Administration; QLFT, qualitative fit test; QNFT, quantitative
46 fit-test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VHP, Vapor-phase
47 hydrogen peroxide.

48

49 **Introduction**

50 The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted
51 in a shortage of personal protective equipment (PPE). In healthcare settings, the need for PPE is
52 critical to protect frontline healthcare providers from infection, and to reduce cross-
53 contamination between patients with coronavirus disease 2019 (COVID-19) and other uninfected
54 patients. In healthcare settings, N95 filtering facepiece (FFP) respirators, including surgical N95
55 respirators, are used to provide protection from airborne infectious particles. The N95
56 terminology refers to the ability to block at least 95 percent of the most penetrating particle sizes
57 (0.1 - 0.3 micron). Proper use of N95 respirators requires qualitative fit-testing (QLFT) or

58 quantitative fit-testing (QNFT), which are designed to ensure a tight face-to-respirator seal for
59 each specific wearer’s facial characteristics.

60 The shortage of N95 respirators resulted from limitations on the required raw materials, limited
61 capacity to manufacture respirators, and the ability of supply and distribution chains to handle
62 increased global demand. For this reason, researchers sought to demonstrate the potential for
63 decontamination and reuse of existing N95 respirators. Standardized procedures are well-
64 established for the decontamination and reuse of medical equipment, such as autoclaving, steam
65 treatment, and chemical inactivation (e.g. bleach) (1). Decontamination of most medical
66 equipment is verified using spore-based biological indicators (2). Unlike most hospital
67 equipment (e.g. steel, metal, plastic) or fabrics (e.g. blankets) for which standardized
68 decontamination methods exist (1), N95 respirators are generally not intended for re-use (3).

69 Thus many of the standard decontamination approaches deform, damage, or destroy the integrity
70 of N95 respirator fabric, nosepiece materials, or elastic straps (4–8). Hydrogen peroxide (H₂O₂)-
71 based methods have been successfully adapted for use in decontamination of N95 respirators (4,
72 6–22), with indications that these methods are less damaging than other decontamination
73 methods (e.g. chemical or steam) and can penetrate the densely-woven fabric of respirator
74 facepieces (4, 6–8, 14, 22). In addition, the viricidal capability of H₂O₂ decontamination methods
75 has been previously demonstrated (23–25). Vapor-phase H₂O₂ methods (e.g. “VHP” and other
76 patented methods) have been used to decontaminate N95 respirators and were granted temporary
77 U.S. Food and Drug Administration (FDA) “Emergency Use Authorization” (EUA) for
78 healthcare use during the pandemic (26). However, these methods employ high concentrations of
79 hydrogen peroxide (30-70%) and elevated temperature to achieve vaporization. Vapor-phase
80 H₂O₂ (VHP) methods at these concentrations may pose increased health risks to decontamination
81 personnel, and combined with elevated temperature, can result in notable respirator material
82 decay (27). Historical aerosolized H₂O₂ (aHP) methods utilize lower peroxide concentrations (5-
83 6%) with silver ions and other antimicrobial agents, activated aerosolization via plasma, nozzle
84 pressure, or ultrasound, with similar limitations to VHP methods (28–32). These methods have
85 not received strong comparative support in U.S. markets due to lower decontamination
86 effectiveness (30–38). Therefore, we utilized a recently-developed aHP method (i.e. the CURIS®
87 system), which dispenses a low concentration hydrogen peroxide solution through a precision
88 adjustable nozzle (39). The unit design and decontamination process characteristics allow

89 consistent distribution of disinfectant over time and enable effective decontamination of space
90 and materials. The aHP approach has the potential to scale up for large clinical settings, since the
91 number of respirators that can be decontaminated simultaneously is limited only by the room
92 size.

93 At present, respirator manufacturers have not approved protocols for N95 respirator
94 decontamination (3). To address imminent pandemic needs, healthcare settings have referenced
95 U.S. Centers for Disease Control and Prevention (CDC) guidelines on provisional N95 respirator
96 decontamination and reuse (40, 41). Battelle Memorial Institute of Columbus, Ohio, received
97 FDA EUA status for an N95 decontamination protocol using a VHP method, based on a prior
98 study addressing the potential for respirator reuse in emergency scenarios (4, 26). This study
99 included evaluation of respirator structure, filtration, and manikin fit-testing, and used bacterial
100 spore-based biological indicators to demonstrate effective decontamination (4); however, viral
101 inactivation testing and respirator fit on live subjects were not performed. Since the current
102 pandemic entails a respiratory viral pathogen, multiple decontamination protocols have been
103 actively investigated at research universities and medical centers (6–21).

104 Given the reduced personnel health risks of using aHP, we assessed the ability of an aHP
105 decontamination protocol to achieve viral and microbial decontamination of N95 respirators,
106 while preserving respirator fit and integrity over multiple treatment cycles. Several respirator
107 models in use by local healthcare and research personnel were included. Viral decontamination
108 was tested using multiple species representing a range of pathogen characteristics: *Pseudomonas*
109 *phi6* bacteriophage (*phi6*), herpes simplex virus 1 (HSV-1), coxsackievirus B3 (CVB3), and
110 SARS-CoV-2. Commercial *Geobacillus stearothermophilus* spore-based biological indicators
111 were used in parallel throughout the aHP process to verify effectiveness of decontamination. We
112 measured the inactivation of viruses by passive drying and by active aHP decontamination.
113 Fitness of respirators for re-use was assessed by qualitative and quantitative respirator fit-testing
114 after decontamination, including up to 10 cycles of aHP treatment. Respirator structure and
115 filtration efficiency testing was also performed. We also acquired real-time and diffusion
116 sampler analyses of hydrogen peroxide levels throughout the decontamination process to monitor
117 user safety.

118 **Results**

119 This study was intended to rigorously evaluate a protocol for decontamination and re-use of N95
120 respirators using aerosolized hydrogen peroxide (aHP) treatment (7% H₂O₂; Curoxide®). The
121 N95 respirator facepiece models examined here represent those frequently used at Penn State or
122 within the Penn State Health system. Six N95 respirator models were selected, with the greatest
123 number available being the 3M 8511 model (Table 1, Figure S1). The decontamination process
124 was performed in the BSL3 enhanced facility, enabling the assessment of viral inactivation
125 across multiple biosafety levels, including SARS-CoV-2 (Table 2, Figure S2). The BSL3 facility
126 employs aHP on a routine basis to decontaminate solid equipment, and we adapted this protocol
127 to account for the absorbent nature of N95 respirators. Standard aHP charge, pulse, and dwell
128 period parameters were adjusted to optimize cycle times (Table 3) and account for biological
129 indicator and virology results. Our final aHP process (matched to room size) utilized a 11:43
130 charge period to establish of aHP, followed by six pulse charges evenly spaced over 30 minutes
131 to maintain H₂O₂ concentrations, and a 20-minute dwell period (Table 3).

132 **Chemical Verification and Biological Validation of Aerosolized H₂O₂ Process**

133 Chemical and bacterial spore-based biological indicators (BIs) were used to verify aHP treatment
134 and decontamination. All chemical indicators located throughout the treatment area (Prep Room)
135 during all aHP cycles confirmed exposure to hydrogen peroxide. For cycles in which charge,
136 pulse, and dwell periods were utilized, all biological indicators (BIs) similarly indicated
137 successful decontamination, with the exception of aHP cycles 3 and 5 (Table 4, Figure S3). In
138 cycle 3 the additional dwell period was not yet implemented, and BIs indicated an unsuccessful
139 decontamination cycle (1 positive, 5 negative). External contamination of one spore coupon after
140 treatment cycle 5 (via dropping) likely resulted in the single positive indicator for this cycle
141 (Table 4). Overall chemical and biological indicator results indicated successful aHP treatment
142 and decontamination of N95 respirators.

143 **Real-Time Hydrogen Peroxide Monitoring**

144 Real-time measurement of H₂O₂ concentrations during decontamination were obtained with a
145 portable, real-time ATI PortaSens II monitor (Table 5). H₂O₂ concentrations in the treatment area
146 were measured at ≥ 120 ppm during the charge and pulse periods (maximum sensor capability).

147 Hydrogen peroxide concentrations outside the sealed entryway were low or undetected (0 ppm).
148 On occasions where a broken seal arose in the tape around the door (Figure S2), low
149 concentrations were detectable outside the door (up to 3 ppm). Once corrected, these levels
150 immediately dropped to 0 ppm. During aeration after aHP treatment, H₂O₂ levels were monitored
151 until concentrations measured ≤ 2 ppm. At this time research personnel entered the Prep Room to
152 measure H₂O₂ concentrations at respirator surfaces. Hydrogen peroxide concentrations were
153 observed to decline rapidly during aeration within 20-30 minutes of door opening (Table 5).
154 Initial respirator surface concentrations (at fabric) typically exceeded 2 ppm. Subsequent
155 respirator drying to achieve < 1 ppm required further room aeration (exhaust ventilation)
156 exceeding two hours, or overnight (Table 5). Once H₂O₂ respirator surface concentrations
157 measured < 1 ppm, they were either subjected to further cycles of aHP, or collected for fit-testing
158 or virus inactivation analysis.

159 **Qualitative and Quantitative Fit-Testing After aHP Decontamination**

160 We employed both qualitative (QLFT) and quantitative (QNFT) fit-testing. QLFT allowed
161 repeated non-destructive testing across multiple rounds of decontamination, while QNFT
162 provided numerical data on fit factor and ruled out any false negatives due to user fatigue. QLFT
163 and QNFT was conducted after the first, fifth, and tenth decontamination cycles for both a male
164 and female subject. These tests included a large number of 3M model 8511 respirators (for which
165 we had the most available in the starting pool), and a smaller number of 5 other respirator models
166 (Table 1, Figure 1). All respirators passed all QLFT and QNFT fit tests (Figure 1). One respirator
167 facepiece (3M model 1870+) experienced a broken strap after the eighth cycle of aHP; this
168 respirator had passed QLFT successfully in earlier cycles but was excluded from final QNFT. No
169 other failures occurred, therefore with 95% confidence, at least 95% of 3M model 8511
170 respirators maintained successful fit seal after ten aHP decontamination cycles. QNFT results
171 with 3M model 8511 respirators passed the minimum passing fit factor of 100, and the maximum
172 quantifiable fit factor of 200(+) in 8 of 9 tests. The numerical range of passing fit factors (100 –
173 200), and available sample quantity, limit any further statistical analysis. The successful fit-
174 testing results indicate that repeated cycles of aHP decontamination do not interfere with
175 respirator fit for reuse.

176 **Respirator Filtration Efficiency Testing**

177 N95 respirator filtration efficiency testing was conducted on aHP-treated 3M 8511 respirators
178 using the NIOSH test protocol under full-load test conditions (Table 6). No visible degradation
179 was found on inspection (e.g. metal nose guard discoloration, unusual thinning, or wear).
180 Filtration efficiencies were found to exceed 95% for all eight respirators subjected to ten cycles
181 of aHP decontamination. Therefore, for at least ten aHP cycles, there were no adverse impacts or
182 loss of N95 respirator efficiencies. Two additional unused, untreated 3M 8511 respirators were
183 additionally tested and found with slightly reduced filtration efficiencies (94.4%, 94.6%),
184 consistent with the respirator manufacturer's 5-year shelf-life limitation. These data indicate that
185 overall respirator performance was maintained over time and after aHP treatment.

186 **Application of Multiple Viral Species to N95 Respirator Facepieces**

187 Viral inactivation on respirator facepieces was anticipated to occur both by the passive process of
188 drying or desiccation, and by the active process of aHP decontamination. Multiple virus species
189 were included to test the decontamination potential of aHP against viruses in general, as well as
190 against SARS-CoV-2. These included phi6, HSV-1, CVB3, and SARS-CoV-2 (see Table 2 and
191 Methods for details). Respirators used for virus inactivation testing were those previously
192 subjected to aHP treatment and fit-testing, to spare overall respirator consumption (see Table 4
193 and Methods). Initial application of virus to different respirator facepiece types revealed clear
194 differences in relative absorption vs. fluid repulsion (Figure S1). 3M respirator models 1870+
195 and 9211+ share a common outer fabric which is listed by the manufacturer as having the highest
196 fluid resistance of any N95 respirator (Table 1) (42). In our testing, these two respirator models
197 displayed no apparent absorption of virus inoculum and instead dried with a "coffee ring effect".
198 All other respirator types (Table 1) experienced a combination of liquid spreading, absorption,
199 and evaporative drying of the virus inoculum droplet. Viruses were inoculated onto different
200 areas of each respirator facepiece model, including the outer and inner fabric surfaces, the elastic
201 strap, and where present, the inner and outer surface of the plastic exhalation valves.

202 **Decontamination of Virus-Inoculated Respirators by Aerosolized H₂O₂ Treatment**

203 We set out to assess the effectiveness of aHP treatment for active decontamination of virus
204 inoculated onto N95 respirators. Virus-inoculated respirators were subjected to aHP treatment,
205 using both "Modification 1" and "Final" parameters (Table 3). Viral testing of decontamination

206 was conducted during five independent aHP cycles (Table 4), using the maximum inoculum titer
207 available for each viral stock preparation. For phi6 bacteriophage, this included 34 “aHP-treated”
208 sites spanning two independent rounds of testing (Figure 2). For HSV-1 and CVB3, this included
209 62 and 60 “aHP-treated” sites respectively, spanning three independent rounds of testing (Figure
210 3 and Figure 4). Across a total of 204 respirator sites inoculated with one of four virus species
211 tested (Table 2; see also Table S1), only four sites had any detectable virus remaining. Three of
212 these rare positive virus plaques were detected in an aHP cycle using the “Modification 1”
213 parameters (Figure 2A and 3A; Table 4; see also Figure S4) – these were a key motivation to add
214 the dwell time for the “Final” aHP cycle parameters (Table 3). Overall, aHP treatment produced
215 a 4-7 log₁₀ reduction in viral load (10⁷ reduction for phi6, Figure 2A; 10⁵ reduction for HSV-1,
216 Figure 3; 10⁴ reduction for CVB3; Figure 4). There was no observable difference in the
217 effectiveness of aHP decontamination for inner vs. outer surfaces of respirators (Figures 2-5; see
218 also Table S1), or in limited testing of alternative inoculation sites such as elastic straps (Figure
219 3, Figure 4, Table S1). The success of virus inactivation by aHP treatment mirrored the results of
220 spore-based biological indicators (Table 4).

221 **Inactivation of Multiple Viral Species by Air-Drying on Respirators**

222 Since passive viral inactivation by drying likely occurs during the time involved in
223 decontamination, we measured the amount of virus remaining on inoculated but untreated N95
224 respirators. For each cycle of viral testing, the duration of passive viral inactivation was matched
225 to the duration of the decontamination process (including aHP treatment, subsequent aeration,
226 and transport). These “drying-only” samples confirmed a partial loss of viral infectiousness,
227 ranging from 10-100-fold for phi6 and HSV-1, and 100-fold or greater for CVB3 and SARS-
228 CoV-2 (Figures 2-5; see also Figure S4 and Table S1). For phi6 bacteriophage, this included 26
229 “drying-only” inoculation sites spanning three independent rounds of testing (Figure 2). For
230 HSV-1 and CVB3, this included 52 “drying-only” inoculation sites for each virus species,
231 spanning four independent rounds of testing (Figure 3 and Figure 4, respectively). Viral
232 inactivation by drying was not markedly different on inner vs. outer surfaces of the respirator
233 models (Figures 2-5; see also Table S1), or in limited testing of alternative inoculation sites, such
234 as elastic straps or plastic exhalation valves (Figure 3A-B, Figure 4A-B, Table S1).

235 **Inactivation of SARS-CoV-2 by aHP Treatment**

236 Experimental testing of SARS-CoV-2 by aHP necessitated that all work be completed at BSL3.
237 These studies were conducted with the 3M 8511, 1860, and 1870+ N95 respirators and included
238 two independent rounds of testing (Figure 5). As with the surrogate virus species, SARS-CoV-2
239 was first inoculated onto respirator facepieces. The “drying only” controls were left in the BSL3
240 ambient environment, while matched samples were subjected to aHP-treatment. The respirators
241 used for SARS-CoV-2 testing had been subjected to 10 prior rounds of aHP before virus
242 inoculation (Table 4). For SARS-CoV-2, viral testing included 48 “drying-only” inoculation sites
243 and 48 “aHP-treated” sites, spanning two independent rounds of testing (Figure 5). We observed
244 a partial loss of viral infectiousness for SARS-CoV-2 due to drying (e.g. $10^{6.125}$ TCID₅₀/mL
245 input vs $\sim 10^2$ TCID₅₀/mL after drying; Figure 5). Importantly, no infectious SARS-CoV-2
246 remained on any respirator model after aHP decontamination (Figure 5).

247 **Discussion**

248 Based on a series of ten respirator decontamination cycles and multiple rounds of viral
249 inactivation testing, multiple N95 respirator models tested were found to be suitable for aHP
250 decontamination and reuse. We found that respirators successfully passed qualitative respirator
251 fit testing after multiple cycles of the aHP decontamination process, and ultimately passed tests
252 indicating no loss in filtration efficiency. Most studies thus far have focused either on verifying
253 fit-testing after respirator decontamination (6–10, 12, 15, 16, 20), or examined how
254 decontamination approaches inactivate one or more virus species on respirators (6–8, 11, 13, 14,
255 18–21). A handful of N95 respirator decontamination studies have combined fit-testing with
256 measures of viral inactivation (6–8), but none incorporated viral- or fit-testing after 5 or 10
257 decontamination cycles as done here, or included the parallel use of biological indicators. Only
258 rarely have studies included extended-use between multiple rounds of decontamination cycles
259 (10), although this is a key aspect of reuse that warrants further study. Our study is unique in
260 including multiple measures of respirator integrity via fit-testing, as well as filtration efficiency,
261 and robust verification of viral inactivation using BIs, multiple surrogate viruses, and SARS-
262 CoV-2 in parallel (22). The breadth of this study aims to extend its usefulness beyond the current
263 pandemic.

264 **Respirator Resilience for Re-Use**

265 Aerosolized H₂O₂ decontamination of the N95 respirators used in this study did not indicate any
266 adverse impact on final respirator filtration efficiency, although extended-use of respirators
267 between aHP cycles was not possible in this study. We documented effective control of H₂O₂
268 levels, supporting effective pathogen decontamination with no detectable researcher exposure.
269 These data support and reflect those of parallel studies that have tested respirator fit after
270 decontamination by other forms of hydrogen peroxide vapor (VHP) and/or similar methods (6–
271 10, 12, 15, 16, 20). Further studies will be needed to assess the H₂O₂ concentration profile inside
272 containment, using real-time instruments with a wider detection range and automated data
273 logging.

274 As noted above, most studies that include successful fit-testing and verification of viral
275 inactivation have not pursued this testing across multiple (i.e. 10) cycles of decontamination (6–
276 8, 20). Lab-based conditions such as those used here do not fully reflect clinical use conditions.
277 While respirators were physically stretched between each decontamination cycle as a proxy for
278 donning and doffing, sustained clinical use includes other stressors which may influence fit and
279 performance (e.g. exhaled moisture or perspiration) (10, 16). However as noted by the CDC,
280 respirators with obvious signs of use (e.g. makeup or patient fluids) should be discarded and not
281 used for decontamination (40, 41). Other studies have explored respirator decontamination in
282 these real-world use scenarios, albeit without including the parallel testing of viral species, BIs,
283 and cycle numbers that were included here (10, 15–17, 20). We anticipate that future studies will
284 address the implementation of aHP-based decontamination in a clinical-use setting.

285 During this study, one 3M 1870+ respirator suffered a broken rubber strap after eight cycles of
286 aHP, during inter-cycle strap stretching. The breakage occurred at a point on the strap that
287 corresponded with a penned hash mark (used to denote decontamination cycle; see Figure S2).
288 There were no other instances of failure for this or any other respirator models. Prior groups have
289 likewise noted strap-based failures after multiple cycles of respirator decontamination (4, 6, 19,
290 20). We recommend using care when marking respirators during re-use protocols.

291 **Viral and Biological Indicator Inactivation**

292 Viral inactivation by drying depends on multiple factors including surface type, humidity,
293 temperature, virion size and type, and duration of drying (43–46). All studies of N95 respirator
294 decontamination include both the passive inactivation of viruses by air drying and their active
295 decontamination by aHP or comparable treatment (43–46). Clinical exposure of respirators to
296 SARS-CoV-2 or other viral pathogens would likewise entail ambient drying prior to any
297 respirator decontamination or re-use (e.g. virus may dry onto an N95 in the course of a work-
298 shift, or during bagging for decontamination or direct re-use). The “drying-only” time frame
299 used here was shorter than used in studies modeling re-use in a clinical setting (10, 15–17, 20).
300 This suggests that crisis-capacity protocols that involve respirator re-use after multiple days of
301 drying, even without aHP or active decontamination, likely provide substantial levels of viral
302 inactivation (40, 41).

303 To model diverse routes of respirator exposure to viral pathogens during use, we inoculated
304 viruses onto different N95 models and surfaces to thoroughly test for the ability of aHP to
305 inactivate viruses. This included different regions of the respirator (e.g. outer vs. inner surface) to
306 discern whether any differences in these fabrics would influence viral inactivation. This work
307 was inspired by early efforts to verify viral inactivation in the context of N95 respirator surfaces,
308 such as that of Kenney *et al* (13). We found scant evidence of viral survival during the aHP
309 decontamination process. Relative to studies using different decontamination methods to test
310 viral inactivation on N95 respirators, these data show equivalent or better inactivation of viruses
311 (6–8, 11, 13, 14, 18–21, 43).

312 Commercial bioindicator tests have been relied upon for verification of decontamination for
313 decades (2, 47). Overall we observed parallel outcomes in terms of successful decontamination
314 of viral species and bacterial spore-based BIs (Table 4), echoing the few other studies that have
315 used these approaches in parallel (14, 18, 20). During establishment of aHP cycle parameters we
316 noted a concomitant failure of BIs and viral inactivation in cycle 3, before the dwell period was
317 added (Tables 3 and 4). The parallels in success or failure of both BIs and viral inactivation
318 suggest that commercial spore-based BIs provide a useful predictor of success or failure for
319 decontamination of N95 respirators, particularly in settings where direct viral testing is not
320 feasible (2, 10, 15–17). The ten cycles of aHP decontamination achieved here are well beyond

321 the CDC's crisis-capacity plans, which recommend no more than five total rounds of respirator
322 reuse (40, 41). While clinical use of respirators, by a multitude of healthcare workers, was not
323 included in the present study, we foresee that such testing will be an important next step.

324 We used multiple virus species to test the viral inactivation capabilities of aHP decontamination.
325 These viruses represented multiple characteristics of human viral pathogens, with a range of
326 virion and genome types and sizes, and previously documented environmental stability (44, 45,
327 48). Like SARS-CoV-1, SARS-CoV-2 has a high level of environmental stability (49–53).
328 Coronaviruses have a lipid-enveloped virion of ~120 nm, with no icosahedral capsid core,
329 containing a single-stranded, linear, positive-sense RNA genome (Table 2). Virions of HSV-1
330 and phi6 bacteriophage have a lipid envelope, with an underlying icosahedral capsid core. In
331 contrast, CVB3 has a non-enveloped or naked icosahedral capsid virus. Prior work has shown
332 that naked-capsid viruses have a higher stability than enveloped viruses, thus demonstrating the
333 range of aHP decontamination abilities (44, 45, 48). While most pathogens utilized here require
334 propagation in mammalian cell lines at biosafety level 2 (BSL2), phi6 can be assayed more
335 flexibly, using rapid bacterial cultures (24-hour turnaround) at biosafety level 1. Phi6 is a natural
336 pathogen of the bacterial species *Pseudomonas syringae pathovar phaseolicola*, which is itself a
337 pathogen of green beans. All viral species examined in this study were effectively
338 decontaminated by aHP (Table 4). While the aerosolization of viruses was not incorporated here,
339 this approach merits inclusion in future studies. Together, the combination of respirator fit
340 testing and virus inactivation testing used here indicate that aHP is a viable decontamination
341 process to enable crisis-capacity reuse of N95 respirators during viral pandemics.

342 **Methods**

343 **Decontamination Facility**

344 The decontamination process was carried out in the Eva J. Pell Laboratory for Advanced
345 Biological Research at The Pennsylvania State University, University Park campus. This facility
346 is a purpose-built BSL3 enhanced facility, and all required approvals were obtained from the
347 Institutional Biosafety Committee (IBC) for work involving viruses, as described below.

348

349 The primary decontamination process was performed within in an approximate 1,700 cubic feet
350 sealed Preparation Room (Prep Room), followed by additional virus inactivation testing with
351 SARS-CoV-2 in a separate, nearby 1,840 cubic feet Prep Room. Procedures and personal
352 protective equipment (PPE) suitable for the viruses and materials in use were strictly observed in
353 this biosafety level 3 (BSL-3) facility, which has consistently maintained institutional, CDC, and
354 USDA approval for work with risk group 3 pathogens since its commissioning in 2014.

355 **Decontamination Preparation**

356 Respirators for decontamination were staged on a portable metal rack located centrally in the
357 Prep Room (Figure S2). Filtered and conditioned air is supplied to the Prep Room and the air
358 exhausted from the room is HEPA-filtered. Bubble-tight dampers (Camfil Farr[®]) were operated
359 to seal both the supply and exhaust air from associated ductwork during the decontamination
360 cycle. The CURIS[®] decontamination unit was programmed, equipment positioned, and the room
361 doors sealed using polyethylene sheeting and non-porous adhesive tape (Figure S2).

362 **Decontamination Process**

363 The CURIS[®] decontamination unit programming method utilizes room size to establish the
364 baseline parameters for charge (initial aHP dispensing) and intermittent aHP pulse periods
365 (additional aerosol pulses). This is followed by a user-defined dwell period (when no further aHP
366 is introduced), at closure of the pulse period. Aeration to disperse residual H₂O₂ follows the
367 dwell period (i.e. room seals are broken and ventilation resumed). Once the user inputs the
368 room's cubic volume or dimensions, the CURIS unit calculates a suggested duration of charge
369 and pulse periods. The standard aeration period is 3 hours, unless an auxiliary scavenging system
370 or other space aeration system is utilized. To account for absorption of aHP into porous materials
371 in the decontamination space (e.g. N95 respirators), a 30-40% increase in these default settings
372 was initially used, as recommended by the manufacturer. Additionally, to ensure adequate
373 contact time of disinfectant to the treated surfaces, a dwell period was added to the continuous
374 and pulse charge periods. Based on initial results, adjustments in the charge, pulse, and dwell
375 periods were made to optimize the decontamination process (Tables 3-4).

376 After completion of the decontamination phase, an aeration or dissipation phase was initiated by
377 removing fixed room seals and opening exhaust dampers for up to 2-hour periods, with the room

378 under slight vacuum (0.18-0.19" W.G.). Adjustments were made to room air exchange rate
379 during aeration to efficiently dissipate detectable H₂O₂ from respirator facepieces. At cycle 5,
380 final parameters were established to include an aeration exhaust rate greater than or equal to 35
381 air changes/hour, with make-up air supplied by outdoor air. Following this phase, and after room
382 H₂O₂ concentration was measured at less than 2 ppm, the respirator-holding rack was either
383 retained under ventilation or transferred to a separate room (referred to as the "Finishing Room")
384 with an HVAC air supply curtain to further dry and decompose residual aHP from respirator
385 facepieces to less than 1 ppm H₂O₂ (24, 25).

386 **Respirator Handling Process**

387 For respirators subjected to repeated rounds of decontamination as part of this study,
388 decontamination cycles were conducted repetitively from staging through drying. In order to be
389 considered "dry" or ready for the next cycle, the interior and exterior respirator surfaces were
390 monitored using a calibrated, hand-held real-time H₂O₂ monitor (ATI PortaSens II). Once H₂O₂
391 concentrations measured at respirator surfaces at less than 1 ppm, respirators were re-staged for
392 the next round of decontamination, or packaged and transported for subsequent respirator fit-
393 testing or virus inactivation analysis. Between each cycle, the treated/dried respirators were
394 subjected to manual stress, by flexing each respirator bi-directionally and stretching each strap
395 twice, using a hold position similar that used in respirator donning or doffing. A standard thin-
396 line VWR Lab Marker was to mark each strap for each round of the aHP process (Figure S2C).

397 **Spore-based Biological Indicators**

398 Commercial biological indicators (BI) were used for verification of decontamination. These
399 commercially-prepared spore discs or "coupons" (Steris Spordex[®]) are enclosed in
400 Tyvek/glassine envelopes (see Figure S3 for image) and contain a mean spore count of 2.4×10^5
401 *Geobacillus stearothermophilus* (ATCC[®] 7953;) (47). Between 6-12 BIs per cycle were placed
402 throughout the room for each decontamination cycle. These were located behind or beneath
403 equipment and surfaces, on the portable metal rack holding respirators, and either on or nested
404 within the pairs of respirators to test aHP penetration (Figure S3). After each cycle, each BI
405 spore disc was transferred from its glassine/Tyvek envelope to tryptic soy broth (Spordex[®]
406 Culture Media), incubated at 55°C, and analyzed after 7 days as an indicator of effective

407 decontamination. There was one instance of a spore disc dropped during transfer, which resulted
408 in a single positive BI from that cycle (cycle 5; see Table 4).

409 **Chemical Indicators of H₂O₂**

410 Chemical indicator strips (Steris Steraffirm[®] or CURIS[®] System Hydrogen Peroxide Test Strips)
411 (between 1 and 4 total per cycle) were placed in various locations throughout the Prep Room to
412 indicate the presence of H₂O₂, supporting successful decontamination.

413 **Real-Time Hydrogen Peroxide Monitoring**

414 The portable ATI PortaSens II detector (PortaSens) was used to measure H₂O₂ levels both within
415 and outside the Prep Room during the decontamination process. Hydrogen peroxide
416 concentrations were also measured at respirator surfaces, and necessarily reduced to less than 1
417 ppm prior to handling and sealing for transportation to designated tissue culture rooms, or for
418 subsequent respirator fit-testing. During the charge and pulse periods of decontamination, real-
419 time instantaneous sampling was conducted through a sealable wall port (designed for sterilizer
420 tubing) into the Prep Room. The PortaSens was also used to monitor Prep Room concentrations
421 at the start of the aeration phase, and to verify concentrations were reduced to less than 2 ppm for
422 safe re-entry to the room (without respiratory protection); these measurements were made at
423 breathing zone height (BZH) or 5 feet above floor level. H₂O₂ concentrations were also
424 monitored outside the Prep Room door seal (see Figure S2), to check for any H₂O₂ leakage.

425 The U.S. Department of Labor/Occupational Safety and Health Administration (OSHA) and the
426 American Conference of Governmental Industrial Hygienists (ACGIH) have established or
427 adopted an eight-hour time-weighted average (TWA) occupational permissible exposure limit
428 (PEL) to hydrogen peroxide of 1 ppm (54, 55). Though researchers and fit-test subjects were not
429 anticipated to experience this eight-hour exposure level, 2 ppm H₂O₂ concentration was used as a
430 safety threshold for room entry, and < 1 ppm for removal of respirators, sealing respirators for
431 transport, and re-use by study participants. See Supplementary Text (and Table S2) for additional
432 metrics used to verify that research personnel were not adversely exposed to H₂O₂.

433 **Respirator Selection for the Study**

434 The N95 respirator facepiece models examined in this study include a range of characteristics,
435 including those identified as surgical N95 respirators (no exhalation valve to maintain sterile
436 field), and non-surgical N95 respirators with an exhalation valve (see Table 1 and Figure S1).
437 Respirator models were required to be successfully fitted by test subjects. Since fit test results
438 varied widely by subject during early testing of Alpha ProTech respirators, this model was
439 discontinued from further study. Fit-testing participants included experienced test subjects and/or
440 administrators. Several respirator models were qualitatively fit-tested (QLFT) using
441 Occupational Safety and Health Administration (OSHA) fit test protocols (saccharine challenge)
442 described in the OSHA Respiratory Protection Standard (29 CFR 1910.134) (56). This included
443 standard exercises to challenge respirator fit, over an approximate 8 minute, 30 second period.
444 Additionally, quantitative fit-testing (QNFT) was conducted using OSHA protocol requirements
445 with a T.S.I, Inc. PortaCount Pro+ Model 8038 Fit Tester. This latter method employs
446 condensation nucleus or particle counting technology (CNC or CPC) to measure aerosol
447 concentration outside and inside the facepiece to determine a user fit-factor (57).

448 **Sample Size and Acceptance Criteria for Fit-Test Reliability**

449 Study design for the QLFT endpoint was intended to rigorously evaluate user respirator to
450 facepiece seal using the greatest-available pool of respirators (stockpiled model 3M 8511), while
451 also providing representative feasibility data for the other respirator models (Table 1). The
452 stockpiled 3M 8511 respirators were procured and collected by Penn State from 2006 to 2009.
453 The use of these respirators beyond the manufacturer's recommended shelf-life enabled the study
454 to proceed without consuming respirators that were more urgently needed by frontline workers,
455 and it was supported by CDC crisis-capacity scenarios in force at the time (40, 41). All other
456 respirator models (Table 1) used in this study were within their expiration date. All respirators
457 new and unused at study initiation.

458 Acceptance criteria for 3M 8511 respirators required a minimum sample of 59 facepieces with
459 no failures during QLFT in order to conclude with 95% confidence that at least 95% of 3M 8511
460 respirators maintain fit integrity after repeated use and decontamination. A total of seventy-seven
461 3M 8511 respirators were available for study purposes. A small number of respirators were
462 allocated for QNFT and virology testing after QLFT, since these processes entailed respirator

463 destruction (i.e. grommet insertion for QNFT or mask slicing for viral resuspension) and
464 rendered them inaccessible for subsequent rounds of aHP.

465 **Respirator Fit-Testing**

466 Prior to decontamination, respirators were labeled with a unique identifier. After
467 decontamination, a hash mark was placed on the lower elastic band of each respirator to identify
468 the round(s) of decontamination completed (Figure S2). Since the study was conducted during
469 the COVID-19 pandemic, physical distancing and active clinical operating conditions limited the
470 use of multiple test subjects. Therefore, two subjects were selected (one male, one female) to
471 maximize varying size and facial features for fit-testing. Respirators were subjected to QLFT on
472 the first, fifth, and tenth rounds of decontamination. A small number of respirators per model
473 were allocated for QNFT during each round of fit testing; due to installation of metal
474 grommet/probe for QNFT, these could not be reused for subsequent aHP cycles or fit testing.
475 These were repurposed for subsequent virus inactivation testing in order to conserve overall
476 respirator use. See Supplementary Text for additional details on QNFT metrics.

477 **NIOSH Filtration Efficiency Testing**

478 To determine whether N95 respirators used in this study experienced filtration media breakdown
479 as a result of sequential aHP disinfection cycles, several respirators were sent for independent
480 laboratory analysis. These included eight 3M 8511 respirators subjected to cyclic aHP treatment
481 and intermittent fit-testing, and two additional unused, untreated 3M 8511 respirators. Respirator
482 filtration efficiency testing was performed by ICS Laboratories, Inc. (ICS) of Brunswick, Ohio.
483 ICS is one of two firms in the U.S. authorized by the National Institute for Occupational Safety
484 and Health (NIOSH) to perform respirator certification or re-certification.

485 An abbreviated “short-cycle” filtration efficiency verification test was conducted using the
486 NIOSH Standard Test Procedure TEB-APR-STEP-0059 (58), which is summarized below. The
487 standard test protocol includes initial respirator conditioning at 85 +/- 5% relative humidity
488 (%RH) and 38 +/- 2°C for 25 hours prior to testing. This conditioning was intended to reflect
489 active moisture load created by the respirator user. Following sealing of the respirator exhalation
490 valve, and placing into the test instrument, full-load testing was performed. This testing included
491 respirator challenge using 200 milligrams sodium chloride aerosol (mean count particle size

492 distribution verified as 0.075 +/- 0.020 microns, with geometric standard deviation not exceeding
493 1.86). Sodium chloride aerosol was neutralized to a “Boltzman equilibrium state” (25 +/- 5°C, 30
494 +/- 10% relative humidity), and introduced at an airflow rate of 85 +/- 4 liters per minute, with
495 periodic check and adjustment to maintain this flowrate. Instrumental analysis was conducted
496 using a T.S.I Automated Filter Tester Model 8130A. Recorded data included flow rate,
497 resistance, penetration, maximum penetration, and filtration efficiency.

498 The test protocol establishes the means for ensuring that the particulate filtering efficiency of
499 N95 series filters used on non-powered respirators submitted for Approval, Extension of
500 Approval, or examined during Certified Product Audits, meets the minimum certification
501 standards set forth in 42 CFR, Part 84, Subpart K, §84.181.

502 **Virus Inoculation and Titration**

503 Viruses used here included herpes simplex virus 1 (HSV-1) strain F, coxsackievirus B3 (CVB3),
504 *Pseudomonas phi6* bacteriophage (phi6) and SARS-CoV-2 isolate USA-WA1/2020. The key
505 characteristics of these viruses are summarized in Table 2. All virus-inoculated materials were
506 handled in accordance with the biosafety level (BSL) specified for that virus (see Table 2).
507 Viruses were propagated in the same host cells as used for viral titration (see virus-specific
508 sections below). In all aHP cycles, the respirators used for virus inactivation testing had been
509 subjected to preceding total number of aHP cycles (see Table 4 for details). The input inoculum
510 for each virus was set to the maximum available in each viral stock preparation.

511 For virus inactivation testing, respirator facepieces were inoculated with a controlled amount of
512 one or more surrogate virus species (refer to Table 2 for complete list). Each virus was added in
513 duplicate (or in quadruplicate during “Post 1-3” cycles of testing) droplets of 10 µL each, on one
514 or more surfaces of each respirator type. The zone of viral inoculation was marked at the corners,
515 to allow excision of the inoculated area after aHP treatment or air-drying. Droplets were allowed
516 to air-dry or absorb fully onto each respirator inside a Class II biosafety cabinet (BSC), before
517 proceeding further. Selected samples of each virus-inoculated respirator were left in ambient
518 conditions, without aHP decontamination, as a “drying-only” virus control. The remainder of
519 each virus-inoculated facepiece was subjected to aHP decontamination as described above (i.e.
520 “decontaminated” samples). For each round of viral testing, the duration of air-drying was
521 matched to the duration of time needed for aHP treatment of parallel respirators (i.e. including

522 transport, respirator staging in the Prep Room, aHP decontamination, aeration, and return to the
523 viral testing location). After aHP treatment, respirators, each virus-inoculated area was cut out of
524 the “dried” or “decontaminated” respirators using dissection scissors. Each excised virus-spot
525 encompassed all layers of the respirator, to capture any virus that had absorbed beyond the
526 surface fabric.

527 **Herpes Simplex Virus 1 and Coxsackievirus B3 Quantification**

528 Excised respirator areas inoculated with HSV-1 or CVB3 were transferred into individual
529 Eppendorf tubes and resuspended in a 250 μ L volume of cell media. Cell media consisted of
530 Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum
531 (FBS) and penicillin-streptomycin (Pen/Strep; 100 U/mL; Thermo Fisher Scientific). The
532 number of infectious units, or plaque-forming units (PFU), for these viruses was determined by
533 limiting dilution onto confluent Vero detector cell monolayers (*Cercopithecus aethiops* monkey
534 kidney cells, ATCC® CCL-81™). Plaque formation was assessed at 72 hours post infection
535 (hpi), after fixation and visualization of plaques using methylene blue staining. Duplicates of
536 each virus-inoculated respirator piece were frozen for titration at a subsequent date, separate
537 from the initial viral quantification. This allowed for experimental redundancy in terms of
538 detector cell monolayers, and reduced handling time for the large numbers of virus-respirator
539 inoculation sites.

540 **Bacteriophage phi6 Quantification**

541 Excised respirator areas inoculated with phi6 bacteriophage were transferred into individual
542 Eppendorf tubes and resuspended in 250 μ L of King’s medium B (KB). These were then
543 quantified on lawns of *Pseudomonas syringae* pathovar *phaseolicola* strain 1448A (*Pph*) using a
544 previously described soft agar overlay protocol (59). Briefly, 100 μ l logarithmic culture of *Pph*
545 ($OD_{600} \sim 0.5$) and 100 μ l of the phage preparation were sequentially added to 3 ml of molten soft
546 agar (0.7%) maintained at 55°C. The mixture was quickly poured on top of a KB agar plate and
547 dried in the biosafety cabinet before transferring to a 28°C incubator. Alternatively, for
548 enumeration of “inoculum” and “dried” samples, soft agar *Pph* lawns were prepared and 10 μ l
549 dilutions of phage preparation were spotted. Plaque forming units (PFU) were enumerated after
550 24-48 hours of incubation at 28°C.

551 **SARS-Coronavirus 2 Quantification**

552 All experiments with SARS-CoV-2 were conducted in the Pell Laboratory under biosafety level
553 3 (BSL3) enhanced conditions using the USA-WA1/2020 isolate. SARS-CoV-2 was spotted onto
554 masks in quadruplicate and treated with aHP or left in ambient BSL3 conditions for drying-only
555 controls. Respirator areas inoculated with SARS-CoV-2 were then excised and resuspended in
556 250 μ L of DMEM supplemented with sodium pyruvate, non-essential amino acids, antibiotics-
557 antimycotics, and 2% FBS. After resuspension, viral titer was determined by tissue culture
558 infectious dose 50 (TCID₅₀) assay in 96-well plates, using Vero E6 cells. Briefly, 20 μ L of
559 resuspended sample was added to 4 wells containing 180 μ L of resuspension media. The added
560 samples were then serially diluted 10-fold down the plate, and the plates were incubated at 37 °C
561 for 96-hours. At this time, cytopathic effect (CPE) was scored, and titer was calculated using the
562 method of Reed and Muench (60).

563 **Acknowledgements**

564 We appreciate the contributions of colleagues and scientists who provided intellectual input
565 and/or materials for this work. These include Joyce Jose, Susan Hafenstein, Anthony Schmitt,
566 Gregory Broussard, Michael Brignati, and Tim Simpson. Paul Turner and his lab graciously
567 provided phi6 bacteriophage. We appreciate the contributions and support of Jim Crandall and
568 the Penn State Environmental Health and Safety staff, as well Theresa Engle and other
569 Occupational Medicine staff, who provided support in study implementation and fit-testing. We
570 also thank Irene Miller and Pell Lab decontamination staff, researchers, clinical staff, as well as
571 Neerav Goyal, Justin Soulier, and the healthcare providers of the Penn State Health Milton S.
572 Hershey Medical Center and College of Medicine.

573 This work was a largely volunteer-based effort, with support from the Pennsylvania State
574 University and The Penn State Institutes of Energy and the Environment. SARS-CoV-2 research
575 in Dr. Troy Sutton's laboratory was initiated by a seed grant from The Huck Institutes of Life
576 Sciences at Pennsylvania State University, and Dr. Sutton's research is further supported by the
577 USDA National Institute of Food and Agriculture, Hatch project 4605.

578

579 **References**

- 580 1. Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee
581 (HICPAC). 2008. Guideline for Disinfection and Sterilization in Healthcare Facilities,
582 2008. Cent Dis Control CDC 163.
- 583 2. Centers for Disease Control and Prevention (CDC), National Center for Emerging and
584 Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion
585 (DHQP). 2008. Guideline for Disinfection and Sterilization in Healthcare Facilities.
586 Sterilizing Pract.
587 [https://www.cdc.gov/infectioncontrol/guidelines/disinfection/sterilization/sterilizing-](https://www.cdc.gov/infectioncontrol/guidelines/disinfection/sterilization/sterilizing-practices.html)
588 [practices.html](https://www.cdc.gov/infectioncontrol/guidelines/disinfection/sterilization/sterilizing-practices.html).
- 589 3. 3M Personal Safety Division. 2020. Disinfection of Filtering Facepiece Respirators. 3M
590 Tech Bull 4.
- 591 4. Battelle Memorial Institute. 2016. Final Report for the Bioquell Hydrogen Peroxide Vapor
592 (HPV) Decontamination for Reuse of N95 Respirators. Prep Contract – Study Number
593 3245 US Food Drug Adm 46.
- 594 5. Liao L, Xiao W, Zhao M, Yu X, Wang H, Wang Q, Chu S, Cui Y. 2020. Can N95
595 Respirators Be Reused after Disinfection? How Many Times? ACS Nano 14:6348–6356.
- 596 6. Kumar A, Kasloff SB, Leung A, Cutts T, Strong JE, Hills K, Gu FX, Chen P, Vazquez-
597 Grande G, Rush B, Lothar S, Malo K, Zarychanski R, Krishnan J. 2020. Decontamination
598 of N95 masks for re-use employing 7 widely available sterilization methods. PLOS ONE
599 15:e0243965.
- 600 7. Smith JS, Hanseler H, Welle J, Rattray R, Campbell M, Brotherton T, Moudgil T, Pack TF,
601 Wegmann K, Jensen S, Jin J, Bifulco CB, Pahl SA, Fox BA, Stucky NL. 2020. Effect of
602 various decontamination procedures on disposable N95 mask integrity and SARS-CoV-2
603 infectivity. J Clin Transl Sci 1–5.
- 604 8. Fischer RJ, Morris DH, van Doremalen N, Sarchette S, Matson MJ, Bushmaker T, Yinda
605 CK, Seifert SN, Gamble A, Williamson BN, Judson SD, de Wit E, Lloyd-Smith JO,
606 Munster VJ. 2020. Effectiveness of N95 Respirator Decontamination and Reuse against
607 SARS-CoV-2 Virus. Emerg Infect Dis 26:2253–2255.
- 608 9. Schwartz A, Stiegel M, Greeson N, Vogel A, Thomann W, Brown M, Sempowski GD,
609 Alderman TS, Condrey JP, Burch J, Wolfe C, Smith B, Lewis S. 2020. Decontamination
610 and Reuse of N95 Respirators with Hydrogen Peroxide Vapor to Address Worldwide
611 Personal Protective Equipment Shortages During the SARS-CoV-2 (COVID-19) Pandemic.
612 Appl Biosaf 25:67–70.
- 613 10. Lieu A, Mah J, Zanichelli V, Exantus RC, Longtin Y. 2020. Impact of extended use and
614 decontamination with vaporized hydrogen peroxide on N95 respirator fit. Am J Infect
615 Control 48:1457–1461.
- 616 11. Cheng VCC, Wong S-C, Kwan GSW, Hui W-T, Yuen K-Y. 2020. Disinfection of N95
617 respirators by ionized hydrogen peroxide during pandemic coronavirus disease 2019
618 (COVID-19) due to SARS-CoV-2. J Hosp Infect 105:358–359.

- 619 12. Grillet AM, Nemer MB, Storch S, Sanchez AL, Piekos ES, Leonard J, Hurwitz I, Perkins DJ.
620 2020. COVID-19 global pandemic planning: Performance and electret charge of N95
621 respirators after recommended decontamination methods. *Exp Biol Med*
622 153537022097638.
- 623 13. Kenney PA, Chan BK, Kortright KE, Cintron M, Russi M, Epright J, Lee L, Balcezak TJ,
624 Havill NL, Martinello RA. 2021. Hydrogen peroxide vapor decontamination of N95
625 respirators for reuse. *Infect Control Hosp Epidemiol* 1–3.
- 626 14. John AR, Raju S, Cadnum JL, Lee K, McClellan P, Akkus O, Miller SK, Jennings WD,
627 Buehler JA, Li DF, Redmond SN, Braskie M, Hoyen CK, Donskey CJ. 2021. Scalable in-
628 hospital decontamination of N95 filtering face-piece respirator with a peracetic acid room
629 disinfection system. *Infect Control Hosp Epidemiol* 42:678–687.
- 630 15. Jatta M, Kiefer C, Patolia H, Pan J, Harb C, Marr LC, Baffoe-Bonnie A. 2021. N95
631 reprocessing by low temperature sterilization with 59% vaporized hydrogen peroxide
632 during the 2020 COVID-19 pandemic. *Am J Infect Control* 49:8–14.
- 633 16. Levine C, Grady C, Block T, Hurley H, Russo R, Peixoto B, Frees A, Ruiz A, Alland D.
634 2021. Use, re-use or discard? Quantitatively defined variance in the functional integrity of
635 N95 respirators following vaporized hydrogen peroxide decontamination during the
636 COVID-19 pandemic. *J Hosp Infect* 107:50–56.
- 637 17. Russo R, Levine C, Grady C, Peixoto B, McCormick-Ell J, Block T, Gresko A, Delmas G,
638 Chitale P, Frees A, Ruiz A, Alland D. 2021. Decontaminating N95 respirators during the
639 COVID-19 pandemic: simple and practical approaches to increase decontamination
640 capacity, speed, safety and ease of use. *J Hosp Infect* 109:52–57.
- 641 18. Christie-Holmes N, Tyli R, Budyłowski P, Guvenc F, Weiner A, Poon B, Speck M, Naugler
642 S, Rainville A, Ghalami A, McCaw S, Hayes S, Mubareka S, Gray-Owen SD, Rotstein OD,
643 Kandel RA, Scott JA. 2021. Vaporized hydrogen peroxide decontamination in a hospital
644 setting inactivates SARS-CoV-2 and HCoV-229E without compromising filtration
645 efficiency of unexpired N95 respirators. *Am J Infect Control* 49:1227–1231.
- 646 19. Ludwig-Begall LF, Wielick C, Jolois O, Dams L, Razafimahefa RM, Nauwynck H,
647 Demeuldre P-F, Napp A, Laperre J, Thiry E, Haubruge E. 2021. “Don, doff, discard” to
648 “don, doff, decontaminate”—FFR and mask integrity and inactivation of a SARS-CoV-2
649 surrogate and a norovirus following multiple vaporised hydrogen peroxide-, ultraviolet
650 germicidal irradiation-, and dry heat decontaminations. *PLOS ONE* 16:e0251872.
- 651 20. Laatikainen K, Mesilaakso M, Kulmala I, Mäkelä E, Ruutu P, Lyytikäinen O, Tella S,
652 Humpi T, Salo S, Haataja T, Helminen K, Karppinen H, Kähkönen H, Vainiola T,
653 Blomqvist K, Laitinen S, Peltonen K, Laaksonen M, Ristimäki T, Koivisto J. 2022. Large-
654 scale decontamination of disposable FFP2 and FFP3 respirators by hydrogen peroxide
655 vapour, Finland, April to June 2020. *Eurosurveillance* 27.
- 656 21. Oral E, Wannomae KK, Connolly RL, Gardecki JA, Leung HM, Muratoglu OK, Durkin J,
657 Jones R, Collins C, Gjore J, Budzilowicz A, Jaber T. 2020. Vaporized H₂O₂
658 decontamination against surrogate viruses for the reuse of N95 respirators in the COVID-19
659 emergency. preprint. *Occupational and Environmental Health*.
- 660 22. Berger D, Gundermann G, Sinha A, Moroi M, Goyal N, Tsai A. 2021. Review of aerosolized
661 hydrogen peroxide, vaporized hydrogen peroxide, and hydrogen peroxide gas plasma in the

- 662 decontamination of filtering facepiece respirators. *Am J Infect Control*
663 S0196655321004314.
- 664 23. Goyal SM, Chander Y, Yezli S, Otter JA. 2014. Evaluating the virucidal efficacy of
665 hydrogen peroxide vapour. *J Hosp Infect* 86:255–259.
- 666 24. Tuladhar E, Terpstra P, Koopmans M, Duizer E. 2012. Virucidal efficacy of hydrogen
667 peroxide vapour disinfection. *J Hosp Infect* 80:110–115.
- 668 25. Holmdahl T, Odenholt I, Riesbeck K, Medstrand P, Widell A. 2019. Hydrogen peroxide
669 vapour treatment inactivates norovirus but has limited effect on post-treatment viral RNA
670 levels. *Infect Dis* 51:197–205.
- 671 26. Hinton, Chief Scientist, Food and Drug Administration D. 2020. FDA Letter - Emergency
672 Use Authorization (EUA) for the Battelle Critical Care Decontamination System (CCDS).
- 673 27. Hultman C, Hill A, McDonnell G. 2006. The physical chemistry of decontamination with
674 gaseous hydrogen peroxide. *Pharm Eng* 27:22–32.
- 675 28. Otter JA, Yezli S. 2011. A call for clarity when discussing hydrogen peroxide vapour and
676 aerosol systems. *J Hosp Infect* 77:83–84.
- 677 29. Boyce JM. 2009. New Approaches to Decontamination of Rooms After Patients Are
678 Discharged. *Infect Control Hosp Epidemiol* 30:515–517.
- 679 30. Fu TY, Gent P, Kumar V. 2012. Efficacy, efficiency and safety aspects of hydrogen peroxide
680 vapour and aerosolized hydrogen peroxide room disinfection systems. *J Hosp Infect*
681 80:199–205.
- 682 31. Holmdahl T, Lanbeck P, Wullt M, Walder MH. 2011. A Head-to-Head Comparison of
683 Hydrogen Peroxide Vapor and Aerosol Room Decontamination Systems. *Infect Control*
684 *Hosp Epidemiol* 32:831–836.
- 685 32. Freyssenet C, Karlen S. 2019. Plasma-Activated Aerosolized Hydrogen Peroxide (aHP) in
686 Surface Inactivation Procedures. *Appl Biosaf* 24:10–19.
- 687 33. Best EL, Parnell P, Thirkell G, Verity P, Copland M, Else P, Denton M, Hobson RP, Wilcox
688 MH. 2014. Effectiveness of deep cleaning followed by hydrogen peroxide decontamination
689 during high *Clostridium difficile* infection incidence. *J Hosp Infect* 87:25–33.
- 690 34. Barbut F, Menuet D, Verachten M, Girou E. 2009. Comparison of the Efficacy of a
691 Hydrogen Peroxide Dry-Mist Disinfection System and Sodium Hypochlorite Solution for
692 Eradication of *Clostridium difficile* Spores. *Infect Control Hosp Epidemiol* 30:507–514.
- 693 35. Shapey S, Machin K, Levi K, Boswell TC. 2008. Activity of a dry mist hydrogen peroxide
694 system against environmental *Clostridium difficile* contamination in elderly care wards. *J*
695 *Hosp Infect* 70:136–141.
- 696 36. Bartels MD, Kristoffersen K, Slotsbjerg T, Rohde SM, Lundgren B, Westh H. 2008.
697 Environmental meticillin-resistant *Staphylococcus aureus* (MRSA) disinfection using dry-
698 mist-generated hydrogen peroxide. *J Hosp Infect* 70:35–41.
- 699 37. Andersen BM, Syversen G, Thoresen H, Rasch M, Hochlin K, Seljordslia B, Snevold I, Berg
700 E. 2010. Failure of dry mist of hydrogen peroxide 5% to kill *Mycobacterium tuberculosis*. *J*
701 *Hosp Infect* 76:80–83.

- 702 38. Beswick AJ, Farrant J, Makison C, Gawn J, Frost G, Crook B, Pride J. 2011. Comparison of
703 Multiple Systems for Laboratory Whole Room Fumigation. *Appl Biosaf* 16:139–157.
- 704 39. Henneman JR, McQuade EA, Sullivan RR, Downard J, Thackrah A, Hislop M. 2022.
705 Analysis of Range and Use of a Hybrid Hydrogen Peroxide System for Biosafety Level 3
706 and Animal Biosafety Level 3 Agriculture Laboratory Decontamination. *Appl Biosaf* 27:7–
707 14.
- 708 40. Centers for Disease Control and Prevention (CDC), National Center for Immunization and
709 Respiratory Diseases (NCIRD), Division of Viral Diseases. 2020. Implementing Filtering
710 Facepiece Respirator (FFR) Reuse, Including Reuse after Decontamination, When There
711 Are Known Shortages of N95 Respirators. *Coronavirus Dis 2019 COVID-19 Decontam*
712 *Reuse Filter Facepiece Respir.* [https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html)
713 [strategy/decontamination-reuse-respirators.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html).
- 714 41. Centers for Disease Control and Prevention. 2020. Strategies for Optimizing the Supply of
715 N95 Respirators. *Cent Dis Control Prev CDC.* [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirators-strategy/index.html)
716 [ncov/hcp/respirators-strategy/index.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirators-strategy/index.html). Retrieved 25 October 2021.
- 717 42. 3M Personal Safety Division. 2021. 3M™ Aura™ Health Care Particulate Respirator and
718 Surgical Mask 1870+, N95. [https://multimedia.3m.com/mws/media/890183O/3m-aura-](https://multimedia.3m.com/mws/media/890183O/3m-aura-healthcare-particulate-respirator-and-surgical-mask-1870-brochure.pdf)
719 [healthcare-particulate-respirator-and-surgical-mask-1870-brochure.pdf](https://multimedia.3m.com/mws/media/890183O/3m-aura-healthcare-particulate-respirator-and-surgical-mask-1870-brochure.pdf). St. Paul, MN.
- 720 43. Rockey N, Arts PJ, Li L, Harrison KR, Langenfeld K, Fitzsimmons WJ, Luring AS, Love
721 NG, Kaye KS, Raskin L, Roberts WW, Hegarty B, Wigginton KR. 2020. Humidity and
722 Deposition Solution Play a Critical Role in Virus Inactivation by Heat Treatment of N95
723 Respirators. *mSphere* 5.
- 724 44. Vasickova P, Pavlik I, Verani M, Carducci A. 2010. Issues Concerning Survival of Viruses
725 on Surfaces. *Food Environ Virol* 2:24–34.
- 726 45. Kampf G, Todt D, Pfaender S, Steinmann E. 2020. Persistence of coronaviruses on
727 inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect* 104:246–251.
- 728 46. Casanova LM, Jeon S, Rutala WA, Weber DJ, Sobsey MD. 2010. Effects of Air
729 Temperature and Relative Humidity on Coronavirus Survival on Surfaces. *Appl Environ*
730 *Microbiol* 76:2712–2717.
- 731 47. Steris Healthcare. Biological Indicators for Sterilization | STERIS.
732 [https://www.steris.com/healthcare/products/sterility-assurance-and-monitoring/biological-](https://www.steris.com/healthcare/products/sterility-assurance-and-monitoring/biological-indicators)
733 [indicators](https://www.steris.com/healthcare/products/sterility-assurance-and-monitoring/biological-indicators). Retrieved 14 October 2020.
- 734 48. Firquet S, Beaujard S, Lobert P-E, Sané F, Caloone D, Izard D, Hober D. 2015. Survival of
735 Enveloped and Non-Enveloped Viruses on Inanimate Surfaces. *Microbes Environ* 30:140–
736 144.
- 737 49. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN,
738 Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ.
739 2020. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N*
740 *Engl J Med* <https://doi.org/10.1056/NEJMc2004973>.
- 741 50. Sizun J, Yu MWN, Talbot PJ. 2000. Survival of human coronaviruses 229E and OC43 in
742 suspension and after drying on surfaces: a possible source of hospital-acquired infections. *J*
743 *Hosp Infect* 46:55–60.

- 744 51. Duan S-M, Zhao X-S, Wen R-F, Huang J-J, Pi G-H, Zhang S-X, Han J, Bi S-L, Ruan L,
745 Dong X-P, SARS Research Team. 2003. Stability of SARS coronavirus in human
746 specimens and environment and its sensitivity to heating and UV irradiation. *Biomed*
747 *Environ Sci BES* 16:246–255.
- 748 52. Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW. 2005. Stability and
749 inactivation of SARS coronavirus. *Med Microbiol Immunol (Berl)* 194:1–6.
- 750 53. Geller C, Varbanov M, Duval R. 2012. Human Coronaviruses: Insights into Environmental
751 Resistance and Its Influence on the Development of New Antiseptic Strategies. *Viruses*
752 4:3044–3068.
- 753 54. Occupational Safety and Health Administration (OSHA), United States Department of
754 Labor. 2017. TABLE Z-1 Limits for Air Contaminants. 1910.1000 TABLE Z–1.
755 <https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1000TABLEZ1>.
- 756 55. American Conference of Governmental Industrial Hygienists (ACGIH). 2019. Hydrogen
757 Peroxide: Threshold Limit Values (TLV) Chemical Substances, 7th ed. Cincinnati, OH.
- 758 56. Occupational Safety and Health Administration (OSHA), United States Department of
759 Labor. 2004. Fit Testing Procedures (Mandatory). 1910.134 App A.
760 <https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.134AppA>.
- 761 57. Operation and Service Manual. 2015. Portacount Pro 8030 and Portacount Pro+ 8038
762 Respirator Fit Testers Rev. P. T.S.I., Inc., Shoreview, MN.
- 763 58. National Institute for Occupational Safety and Health. 2019. Determination of Particulate
764 Filter Efficiency Level for N95 Series Filters Against Solid Particulates for Non-Powered,
765 Air-Purifying Respirators Standard Testing Procedure (STP), p. 9. *In* TEB-APR-STEP-
766 0059 Revision 3.2. <https://www.cdc.gov/niosh/npptl/stps/apresp.html>.
- 767 59. Hockett KL, Baltrus DA. 2017. Use of the Soft-agar Overlay Technique to Screen for
768 Bacterially Produced Inhibitory Compounds. *J Vis Exp* <https://doi.org/10.3791/55064>.
- 769 60. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. *Am J*
770 *Epidemiol* 27:493–497.
- 771 61. Advanced Chemical Sensors. AIHA-LAP ID No. 102047. Longwood, Florida.
- 772 62. SGS Galson Laboratories. AIHA-LAP ID No. 100324. E. Syracuse, New York 13057.
- 773

774 **Tables**

775 **Table 1: N-95 respirator facepiece models included in this study**

Brand & model	# in study	Style	Type	Exhalation valve	Notes
3M 8511	77	molded	Non-surgical	yes	
3M 1860	10	molded	Surgical	no	
3M 1870+	11	folded	Surgical	no	Highest fluid resistance*
3M 9211+	12	folded	Non-surgical	yes	Same fabric as 1870+
Honeywell Sperian N11125	5	molded	Non-surgical	yes	
Alpha ProTech	65	folded	Surgical	No	

776 * Highest level of fluid resistance according to ASTM F1862 at 160 mm Hg (42).

777
778

779 **Table 2. Characteristics of virus species used to test inactivation by aerosolized**
780 **H2O2, as compared to SARS-CoV-2**

Virus species (abbreviation, taxonomic family)	Diameter	Capsid / virion shape	Genome type, ~size*	Titer inactivated by aHP^	Biosafety Level (BSL)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, <i>Coronaviridae</i>)	120 nm	Enveloped, no icosahedral capsid	linear (+) ssRNA genome, ~30 kbp	1.6×10^5 PFU/ml	BSL3
Herpes simplex virus 1 (HSV-1, <i>Herpesviridae</i>)	200 nm	Enveloped, icosahedral	linear dsDNA genome, ~152 kbp	2.0×10^6 PFU/ml	BSL2
Coxsackie virus B3 (CVB3, <i>Picornaviridae</i>)	30 nm	Non-enveloped (naked), icosahedral	linear (+) ssRNA genome, ~7.4 kbp	5.9×10^4 PFU/ml	BSL2
<i>Pseudomonas phi6</i> bacteriophage (phi6, <i>Cystoviridae</i>)	85 nm	Enveloped, icosahedral	segmented, dsRNA genome, ~13.3 kbp	2.4×10^8 PFU/ml	BSL1

781 *ds, double-stranded; ss, single-stranded; ssRNA genomes are either (+) positive or (-) negative sense.

782 ^Each viral species was tested for decontamination at the maximum available titer.

783

784 **Table 3: Optimization of aHP treatment parameters**

aHP Cycle #	Room Volume (ft³)	Charge Period	Pulse Period	Dwell Period	aHP Parameter Set
1a	1700	16:20	40:00	0:00	Initial
1b	1700	16:20	40:00	0:00	Initial
2	1700	11:43	30:00	0:00	Modification 1
3	1700	11:43	30:00	0:00	Modification 1
4	1700	11:43	30:00	0:00	Modification 1
5	1700	11:43	30:00	20:00	Final
6	1700	11:43	30:00	20:00	Final
7	1700	11:43	30:00	20:00	Final
8	1700	11:43	30:00	20:00	Final
9	1700	11:43	30:00	20:00	Final
10	1700	11:43	30:00	20:00	Final
11	1700	11:43	30:00	20:00	Final
12	1700	11:43	30:00	20:00	Final
Post 1	1840	12:41	30:00	20:00	Final*
Post 2	1840	12:41	30:00	20:00	Final*
Post 3	1840	12:41	30:00	20:00	Final*

785 * These cycles were carried out in a larger room, which necessitated adjustment to the charge
786 time to account for the larger room volume.

787

788 **Table 4: Spore-based Biological indicator (BI) and Virus Inactivation Results**

aHP Cycle #	aHP-treated Spore-based BIs	Control Spore-based BIs	Spore-based BI Results	aHP parameter set	Viruses Tested*	Virus Inactivation Results
1a	12	1	PASS	Initial		
1b	12	1	PASS	Initial		
2	--	--	--	Modification 1		
3	6	1	FAIL (1+/5-)	Modification 1	phi6, HSV1, CVB3	3 of 64 sites positive
4	6	1	PASS	Modification 1		
5	6	1	FAIL^ (1+/5-)	Final		
6	6	1	PASS	Final	HSV1, CVB3	1 of 26 sites positive
7	6	1	PASS	Final		
8	6	1	PASS	Final		
9	6	1	PASS	Final		
10	6	1	PASS	Final		
11	6	1	PASS	Final		
12	6	1	PASS	Final		
Post 1	--	--	--	Final	phi6, HSV1, CVB3	0 of 66 sites positive
Post 2	12	1	PASS	Final	SARS-CoV-2	0 of 24 sites positive
Post 3	12	1	PASS	Final	SARS-CoV-2	0 of 24 sites positive

789 * The N95 respirators used for virus inoculation at each cycle were subjected to all preceding aHP cycles
 790 – e.g. respirators used for viral testing in aHP cycle #6 had been through 5 prior aHP cycles. For cycles
 791 labeled “Post”, the respirators for viral testing had been through 10-12 prior aHP cycles.

792 ^A spore disc dropped during transfer to media was the suspected cause of this failure.

793

794 **Table 5: Portable real-time H₂O₂ measurements, using ATI PortaSens II**

aHP Cycle ID	Measurement Location*	Measurement Condition	H ₂ O ₂ Concentration or range (ppm)**	Time period to decayed concentration (minutes)	aHP Parameter set
1a	IC, wall port	Charge	> 120	--	Initial
1a	IC, wall port	Aeration, to entry	2.5 – 57	52	Initial
1b	IC, wall port	Charge	> 120	--	Initial
2	No data	No data	No data	No data	Modification 1
3	IC, door open	Aeration, to entry	1.5 – 11.6	20	Modification 1
3	IC, door open	Aeration, to respirator measurement	1.5 – 0.8	40	Modification 1
4	IC, door open	Aeration, to entry	2 – 10.6	20	Modification 1
4	respirator surface	After overnight drying	0 – 3	overnight	Modification 1
5	IC, wall port	Charge	> 120	--	Final
6	IC, wall port	Pulse	120	--	Final
6	respirator surface	After overnight drying	0	overnight	Final
7	IC, wall port	Charge	> 120	--	Final
7	OC, seal check(s)	Charge, Pulse, Dwell	0	--	Final
7	IC, door open	Aeration, to entry	2 – 7	27	Final
7	respirator surface	After overnight drying	0	overnight	Final
8	IC, wall port	Pulse	88	--	Final
9	IC, wall port	Charge	> 120	--	Final
9	IC, door open	Aeration, to entry	1.6 – 24	20	Final
9	respirator surface	Aeration, to respirator measurement	< 1	85	Final
10	OC, seal check	Pulse, door seal repair	0 – 1.6	--	Final
10	IC, door open	Aeration, to entry	1.3 – 15	32	Final
10	respirator surface	After overnight drying	< 1	overnight	Final
11	IC, door open	Aeration, to entry	1 – 13.6	35	Final
11	respirator surface	After overnight drying	< 1	overnight	Final
Post	respirator surface	Aeration to 1ppm, respirator data log	1 – 8.1	150	Final

795 * Measurement Location: IC – inside containment / treatment area, (wall port) – through sealable wall
 796 port, (door open) – door ajar after door seal removed, OC – outside containment / treatment area, (seal
 797 check) – Prep Room door tape seal, (respirator surface) – at respirator surface following room entry.

798 ** Low measurement value represents lowest concentration following concentration decay; high value
 799 represents starting concentration (prior to decay).

800

801 **Table 6: Respirator filtration efficiency testing results following 10 cycles of**
 802 **aerosolized hydrogen peroxide decontamination**


Full-loading efficiencies – 3M Model 8511 (N95 respirator)*						
Sample ID**	Initial Test Flow Rate (LPM)	Initial Test Resistance (mmH ₂ O)	Initial Test Penetration (%)	Maximum Penetration (%)	Filter Efficiency*** (%)	Result
MS – 1	84	6.5	0.67	2.29	97.71	Pass
MS – 2	85	6.7	0.82	2.38	97.62	Pass
MS – 3	84	6.9	1.46	4.16	95.84	Pass
MS – 4	85	6.8	1.75	4.14	95.86	Pass
FS – 1	85	7.1	2.02	4.58	95.42	Pass
FS – 2	84	6.6	1.47	3.5	96.50	Pass
FS – 3	85	6.6	0.20	2.37	97.63	Pass
FS – 4	86	7.0	1.47	4.12	95.88	Pass
Test specification	81-89			≤ 5.0	≥ 95.0	

803 * Respirator testing analysis performed by ICS Laboratories of Brunswick, OH

804 ** MS, FS – [x]Male subject or female subject sample respirator id

805 ***Filter efficiency percent is based on maximum penetration value.


806 **Figures**



807
 808 **Figure 1: Sequential fit testing (QLFT & QNFT) of N95 respirators subjected to repeated**
 809 **aHP decontamination cycles.**

810 Results demonstrate that all 3M model 8511 respirators successfully pass QLFT and QNFT after
 811 1, 5, and 10 cycles. In particular, 8 of 9 QNFT results for the 3M model 8511 respirator
 812 surpassed a fit factor of 200, the maximum reportable by the test method – providing qualitative,
 813 yet objective, evidence of the safety margin related to fit integrity after 10 aHP decontamination
 814 cycles. All respirator models except Alpha Protech (which had inconsistent fit-test results; see
 815 Methods for details) passed all QLFT and QNFT to which they were subjected. Models Alpha
 816 ProTech (aHP cycle 1) and Kimberly Clark (aHP cycle 2) were only included for a single cycle
 817 and are thus not shown here.

818




819

820 **Figure 2: Infectious titer of phi6 bacteriophage inoculated on N95 respirator facepieces was**
821 **eliminated after aerosolized H₂O₂ (aHP) decontamination.**

822 (A) Data are plotted for each aHP cycle in which viral testing was done (see Table 4). Multiple
823 models of N95 respirator (see Table 1) were inoculated and either treated as “drying only”
824 controls (red) or subjected to aHP treatment (blue). The respirator surface and model are
825 indicated by the symbol shape and fill. The median of all points within a given aHP cycle and
826 treatment is indicated by a solid horizontal line. The dashed horizontal line indicates the limit of
827 detection (LOD) at 1 viral plaque-forming unit (PFU), in the resuspended but undiluted volume
828 from the site of viral inoculation. (B) Image depicts Petri dish plating of bacterial lawns exposed
829 to phi6 from drying-only (left side) or aHP-treated (right side) respirator inoculation sites. These
830 were applied to the bacterial lawn either as an undiluted resuspension (top row) or 1:10⁶ dilution
831 applied to focal points (bottom row). For the purposes of illustrating the decontaminated sites
832 where zero plaques were detected, these numbers were replaced with fractional values (0.5), to
833 allow their visualization on this log-scale plot. See Table S1 for all data values.

834




835

836 **Figure 3: Infectious titer of HSV-1 inoculated on N95 respirator facepieces was reduced by**
 837 **drying and eliminated after aerosolized H₂O₂ (aHP) decontamination.**

838 Data are plotted for each aHP cycle in which viral testing was done (see Table 4). For HSV-1,
 839 the sole positive plaque after aHP treatment occurred in aHP cycle #3, when the “Modification
 840 1” parameters were in use (Tables 3-4). This failure, in concert with a spore-based biological
 841 indicator and 2 CVB3 plaques (Figure 4) motivated the addition of a “dwell time” in the final
 842 aHP parameters. As in Figure 2, multiple models of N95 respirator (see Table 1) were inoculated
 843 and either treated as “drying only” controls (red) or subjected to aHP treatment (blue). The
 844 respirator surface and model are indicated by the symbol shape and fill. The median of all points
 845 within a given aHP cycle and treatment is indicated by a solid horizontal line. The dashed
 846 horizontal line indicates the limit of detection (LOD) at 1 viral plaque-forming unit (PFU), in the
 847 resuspended but undiluted volume from the site of viral inoculation. For the purposes of
 848 illustrating the decontaminated sites where zero plaques were detected, these numbers were
 849 replaced with fractional values (0.5), to allow their visualization on this log-scale plot. See Table
 850 S1 for all data values.

851




852

853 **Figure 4: Infectious titer of CVB3 inoculated on N95 respirator facepieces was reduced by**
 854 **drying and eliminated after aerosolized H₂O₂ (aHP) decontamination.**

855 Data are plotted for each aHP cycle in which viral testing was done (see Table 4). For CVB3,
 856 two positive plaques after aHP treatment occurred in aHP cycle #3, when the “Modification 1”
 857 parameters were in use (Tables 3-4). This failure, in concert with a spore-based biological
 858 indicator and 1 HSV-1 plaques (Figure 4) motivated the addition of a “dwell time” in the final
 859 aHP parameter. The only other positive CVB3 plaque after aHP treatment occurred in aHP cycle
 860 6 (B), and no plaques were detected in the replicate or in parallel samples. As in Figure 2,
 861 multiple models of N95 respirator (see Table 1) were inoculated and either treated as “drying
 862 only” controls (red) or subjected to aHP treatment (blue). The respirator surface and model are
 863 indicated by the symbol shape and fill. The median of all points within a given aHP cycle and
 864 treatment is indicated by a solid horizontal line. The dashed horizontal line indicates the limit of
 865 detection (LOD) at 1 viral plaque-forming unit (PFU), in the resuspended but undiluted volume
 866 from the site of viral inoculation. For the purposes of illustrating the decontaminated sites where
 867 zero plaques were detected, these numbers were replaced with fractional values (0.5), to allow
 868 their visualization on this log-scale plot. See Table S1 for all data values.

869

SARS-CoV-2 titer after drying or aHP treatment



870

871 **Figure 5: Infectious titer of SARS-CoV-2 inoculated on N95 respirator facepieces was**
872 **reduced by drying and eliminated after aerosolized H₂O₂ (aHP) decontamination.**

873 (A-B) Data are plotted separately for each aHP cycle in which viral testing was done (see Table
874 4). For SARS-CoV-2, no infectious virus was detected by TCID50 assay after aHP treatment. As
875 in Figure 2, multiple models of N95 respirator (see Table 1) were inoculated and either treated as
876 “drying only” controls (red) or subjected to aHP treatment (blue). The respirator surface and
877 model are indicated by the symbol shape and fill. The median of all points within a given aHP
878 cycle and treatment is indicated by a solid horizontal line. Viral titer was determined by tissue
879 culture infectious dose 50 (TCID50) assay in 96-well plates, with a limit of detection (LOD) of
880 1.2 (see Methods for details). For the purposes of illustrating the decontaminated samples where
881 no virus was detected, these numbers were plotted as a value of 1. See Table S1 for all data
882 values.

883

884 **Supplementary Text**

885 **Methods for hydrogen peroxide diffusion sampling (by H₂O₂ vapor monitors)**

886 Diffusion samplers, also known as hydrogen peroxide vapor monitors (HPMs) were utilized to
887 monitor long-duration H₂O₂ leakage outside the Prep Room entry (outside containment or OC),
888 on research personnel during decontamination activities (breathing zone samples, clipped to
889 lapel-collar), and within sealed respirator transport containers (prior to fit-testing) to verify that
890 H₂O₂ concentrations remained less than 1 ppm throughout transport and fit-testing. Once the
891 decontamination process was standardized with specific room ventilation parameters, ongoing
892 personnel monitoring was discontinued.

893 HPM sampler analysis was conducted by Advanced Chemical Sensors, Inc. (ACS) of
894 Longwood, FL utilizing an ACS HP-10 hydrogen peroxide vapor monitor, via modified OSHA
895 Method VI-6 (colorimetric analysis). Analysis was subcontracted and completed by laboratories
896 participating in the American Industrial Hygiene Association (AIHA) Laboratory Accreditation
897 Program. The AIHA is an ISO/IEC 17025 accrediting body (61, 62).

898 **Additional methods on quantitative fit-testing metrics**

899 Based on historical studies by the QNFT device and respirator manufacturers, N95 respirators
900 have maximum breakthrough for particle sizes of 0.1 – 0.3 micron. Particles smaller or larger
901 than this size range have increased filtration efficiency (greater than 95%). QNFT fit testing of
902 N95 respirators therefore focuses on measuring this maximum penetration size range, to ensure
903 that detectable leakage was due to facepiece seal leakage. OSHA has established a minimum
904 QNFT passing fit factor of 100 for half-face respirators (including N95s or filtering-facepiece
905 respirators) (56). The QNFT instrument manufacturer has established a maximum quantifiable fit
906 factor of 200, as limited by measurement reliability and particle counting factors. QNFT fit
907 factors equal to or exceeding 200 are therefore reported as 200(+). The reported QNFT data were
908 utilized to verify successful fit reported by QLFT.

909 **Results for hydrogen peroxide diffusion sampling (by H₂O₂ vapor monitors)**

910 Diffusion samplers, also known as hydrogen peroxide vapor monitors (HPMs) were utilized to
911 assess researcher exposure levels to H₂O₂, with reference to the OSHA permissible exposure
912 limit (PEL) and ACGIH Threshold Limit Value (TLV[®]) of 1 ppm, as an eight-hour time-

913 weighted average (TWA). HPMs were also collected to monitor H₂O₂ build-up within respirator
914 containers prior to fit-testing (for test subject safety), and to verify that H₂O₂ concentrations
915 remained low in areas occupied by researchers (outside containment, OC) during the
916 decontamination process (Table S2). All personal breathing zone HPM sampler results were
917 reported below sample detection limits (< 0.08 ppm, <0.1 ppm) for researchers conducting aHP
918 processes (up to 3 hours). All results for HPMs placed within sealed transport containers were
919 reported below sample detection limits (< 0.03 ppm), indicating no residual H₂O₂ present
920 through transport and respirator fit-testing. All results for HPMs collected as OC samples were
921 reported below sample detection limits (< 0.08 ppm, cycle 1b) and < 0.2 ppm (cycle 11).
922

923 **Supplementary Tables**

924 **Table S1 (Excel): aHP Viral Testing Values**

925 Excel file of data underlying Figures 2-4, and Table 4. These include the number of plaque-
 926 forming units (PFU) for phi6, HSV-1, and CVB3, as well as TCID50(log10)/mL values for
 927 SARS-CoV-2. As noted in Figures 2-4, for samples where no virus was detected, these numbers
 928 were replaced with non-zero values to allow their visualization on the log-scale plots in Figures
 929 2-4. HSV-1, CVB3, and phi6 "no virus detected" values were set to 0.5 (less than 1 plaque
 930 detected), and SARS-CoV-2 values were set to 1 (less than the limit of detection of 1.2
 931 TCID50(log10)/mL).

932

933 **Table S2: Hydrogen peroxide diffusion sampler (HPM) data**

aHP Cycle ID	Sample Type	Location Notes*	H₂O₂ (ppm)**	Sampling Period (minutes)***
1a	Researcher A – personal breathing zone	Sampler at worker lapel; transit in all service areas	< 0.1	143
1b	Researcher B – personal breathing zone	Sampler at worker lapel; transit in all service areas	< 0.08	185
1b	area sample	Door Seal (OC), breathing zone height	< 0.08	183
1b	respirator container	3M 1860 (within brown paper bag)	< 0.03	461
1b	respirator container	3M 9211+ (bag)	< 0.03	518
1b	respirator container	Alpha Protech PFL (within brown paper bag)	< 0.03	497
1b	respirator container	Alpha Protech PFL (within brown paper bag)	< 0.03	510
11	area sample	Door Seal (OC), breathing zone height	< 0.2	110


934 *C (charge period), P (pulse period), D (dwell period), A (aeration phase)

935 ** “< Value” indicates sample analysis was below limit of quantitation (LOQ) based on sampler diffusion
 936 rate and air volume collected. Time-weighted average (TWA) not calculated for results reported <LOQ.
 937 The OSHA PEL and ACGIH TLV[®] exposure standard for hydrogen peroxide is 1ppm eight-hour TWA.

938 ***Sampling period varied by sampling objectives.

939

940 **Supplementary Figures**




941

942 **Figure S1: Respirator facepiece models & characteristics**


943 (A) 3M models 1860 and 8511 (left) have a molded facepiece, with 8511 including an exhalation
944 valve. (B) Virus-inoculation via droplets spotted onto the respirator fabric are shown for two
945 examples. (C) 3M models 1870+ and 9211+ share a common folded fabric model, with a high
946 fluid resistance of the fabric. 3M 9211+ includes an exhalation valve. Several of the facepieces
947 (1860, 1870+, 9211+) display the metal grommet from insertion of the probe used for
948 quantitative fit testing (QNFT). The inner face of each respirator is shown, which for the models
949 shown in (C) required a prop to hold them open.

950



951
952 **Figure S2: Respirator staging and CURIS® unit.**
953 (A) Respirator staging (partial loading) on metal rack with binder clips and rack centrally
954 positioned in the Prep Room. (B) Prep Room door sealed with polyethylene sheeting and non-
955 porous adhesive tape to prevent migration of H₂O₂ outside of the Prep Room. (C) Indelible ink
956 pen hash marks (arrows) placed to notate completed aHP cycle, at time of cycle completion, or
957 collection/transport for subsequent fit-testing or virus inactivation testing. (D) CURIS®
958 decontamination unit with adjustable aHP dispersal nozzle and programmable inputs.

959




960

961 **Figure S3: Spore-based biological indicators**

962 (A) Commercial biological indicator (BIs; Steris Spordex[®]) containing *Geobacillus*
963 *stearothermophilis* spores are sold on discs in Tyvek/glassine envelopes, with accompanying
964 vials of culture media. After treatment, spore discs are transferred from to culture media and
965 incubated for at 55°C for at least 7 days post decontamination cycle. (B) Media color change to
966 yellow indicates bacterial growth, as seen in the positive control tube on the far right. In addition
967 to placement of BIs around the treatment room (see Methods for details), BIs were nested
968 between two molded respirators (3M 1860) and taped together (C), were enclosed within a flat-
969 fold type respirator (3M Aura 9211+; not pictured). All BIs positioned in this manner were
970 rendered inactivated after aHP treatment.

971

972



973

974 **Figure S4: Viral titration demonstrates inactivation and loss of infectious units due to**
975 **drying and aerosolized H₂O₂ (aHP) decontamination**

976 Shown here are representative examples of serial dilutions (titration) of HSV-1 or CVB3 that
977 were spotted onto 3M 9211+ respirators, and then resuspended and plated onto monolayers of
978 Vero detector cells. Viral plaques, which are visible as clear foci of infection (plaque-forming
979 units, or PFU) on the background of methylene blue-stained cells, were visualized at 72 hours
980 post infection. The plate shown in (A) illustrates serial dilution of a high concentration of HSV-1
981 after drying-only (10^5 PFU; see plot in Figure 3A), and a lower concentration of CVB3 after
982 drying-only (10^2 PFU; see plot in Figure 4A). The plate shown in (B) is from an aHP cycle run
983 with "Modification 1" parameters, when no dwell time was used (aHP cycle 3; see Tables 3-4)
984 and commercial spore-based biological indicators indicated a failure of decontamination. Even
985 on this partial aHP decontamination, this sensitive detection method revealed only three wells (of
986 which two are shown above) with any viral plaques (indicated by arrowheads; these equate to 25
987 PFU of HSV-1, and 5 PFU of CVB3; see plots in Figure 3A and 4A).

988